Agenus Inc - Company Profile
Powered by
All the data and insights you need on Agenus Inc in one report.
- Save hours of research time and resources with
our up-to-date Agenus Inc Strategy Report
- Understand Agenus Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Agenus Inc (Agenus), formerly, Antigenics Inc, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.
Agenus Inc premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Vaccines Pipeline: | Stimulon |
PhosphoSynVax for Cancers | Prophage |
AutoSynVax for Cancers | Retrocyte Display |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Regulatory Approval | In April, the company was granted Fast Track Designation from the US Food and Drug Administration (FDA) for Botensilimab and Balstilimab in Colorectal Cancer. |
2022 | Contracts/Agreements | In December, the company and The University of Kansas Cancer Center entered into an agreement with Targovax ASA to run a clinical trial testing mutant RAS vaccine TG01 in combination with PD-1 CPI balstilimab in pancreatic cancer. |
2022 | Contracts/Agreements | In October, the company and VBI Vaccines Inc. announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal antibody targeting the programmed death receptor-1 protein. |
Competitor Comparison
Key Parameters | Agenus Inc | AbbVie Inc | Novartis AG | Amgen Inc | Boehringer Ingelheim International GmbH |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Switzerland | United States of America | Germany |
City | Lexington | North Chicago | Basel | Thousand Oaks | Ingelheim am Rhein |
State/Province | Massachusetts | Illinois | - | California | Rheinland-Pfalz |
No. of Employees | 389 | 50,000 | 76,057 | 26,700 | 53,000 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Garo H. Armen, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 1999 | 70 |
Craig Winter | Chief Information Officer | Senior Management | 2021 | - |
Robin E. Abrams | Chief Legal Officer | Senior Management | 2022 | - |
Stephanie Fagan | Chief Communications Officer | Senior Management | 2023 | - |
Tracy Mazza Clemente | Chief People Officer | Senior Management | 2022 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward